B cell Antibody Discovery – ANTI-PD1 CASE STUDY

Published on January 16, 2023

Your discovery program deserves the best. Through B Cell discovery your program will benefit from reduced timelines and quality data earlier to enable the delivery of a diverse, better characterised panel of recombinant antibodies.

Find out more about how B cell discovery can improve your discovery program.

The post B cell Antibody Discovery – ANTI-PD1 CASE STUDY appeared first on abzena.

Continue reading on website
Other news

The value of capability in allogeneic cell therapy: an interview with Andy Holt

January 16, 2023
In this interview, we spoke to Andy about Cellistic’s recent acquisition of a GMP facility and how their newly increased capabilities will help them make a bigger difference in bringing iPSC-based allogeneic cell therapies to patients faster. Plus, Andy gave us a sneak peek into some of Cellistic’s upcoming projects and his predictions for how the iPSC landscape will evolve in the next five years.

15 critical business questions keeping pharma leaders up at night

January 17, 2023
To ensure success in today’s evolving pharmaceutical marketplace, you need answers to critical business questions at each step of the drug development life cycle. Is your organization equipped to answer these burning questions? Business Development 1. Of all assets available, what asset has the highest potential and is most likely to give me the patient […]